Interventional Cardiology
Medical Education
B.A.: Drew University, Madison, New Jersey, 1975
Ph.D.: St. Louis University, St. Louis, Missouri, 1979
Fellowship: Postdoctoral Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, Missouri, 1979
Medical Degree: University Of Connecticut, Storrs, Connecticut, 1983
Residency: Internal Medicine, Barnes Hospital, Washington University School of Medicine, St. Louis, Missouri, 1986
Fellowship: Postdoctoral Cardiology, Yale University School of Medicine, New Haven, Connecticut, 1989
Fellowship: Intervential Cardiology, Yale University School of Medicine, New Haven, Connecticut, 1990
Honors and Awards
Listed in Best Doctors in America, 2003-2013 (Best Doctors, Inc.)
Hugh McCulloch Award Recipient, 2011
Disclosure of Financial Interests with IndustryWashington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.
Dr. John M. Lasala reported the following earned financial interests during calendar year 2011. Move your mouse over a header for more info.
| Company | Royalties Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product. | Consulting &
Advisory Boards Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board. | Speaker Fees Speaker Fees: Companies may pay faculty to speak to professional audiences about their products. |
| AGA Medical | | $10,001-$25,000 | $1,000-$10,000 |
| Boston Scientific | | $10,001-$25,000 | |
| Eli Lilly | | | $50,001-$100,000 |
| Abiomed | | | $50,001-$100,000 |
To learn more about Washington University's policies on collaborations with industry,
click here.
Editorial Responsibilities
Circulation: Cardiovascular Interventions
Catheterization & Cardiovascular Intervention
American Journal of Cardiology
American Heart Journal
Journal of Thoracic Surgery
Journal of Hypertension
Video Journal of Cardiology
The Interventional Fellows Institute
Journal of Invasive Cardiology
Interventional Cardiology Test Committee for American Board of Internal Medicine
Invited Publications
Baran K, Lasala J, Cox D, Mascioli S, Song A, Deshpande M, Jacowski M, Dawkins K: A Clinical Risk Score for Prediction of Very Late Stent Thrombosis in Drug-Eluting Stent Patients.
EuroIntervention 2011; Mar;6(8):949-54
Brilakis ES, Lasala JM, Cox DA, Berger PB, Bowman TS, Starzyk RM, Dawkins KD: outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance)program. JACC Cardiovasc Interv. 2010; July;3(7): 742-50
Banerjee S, Lasala JM: Left-to-Right Shunt Closure. Cardiac Interventions Today September/October 2010
Lin H, Lasala JM: “Chapter 7: Image Guidance of SHD Interventions:Ultrasound-ICE”. Manual of Adult Structural Heart Disease Interventions. Submitted November 2010
Cox D, Ellis S, Lasala JM, Ormiston J, Stone G, Turco M, Mikhail G, Gerber R, Colombo: “Influence of Sex on Long-Term Outcomes after Percutaneous Coronary Intervention with the Paclitaxel-Eluting Coronary Stent: Results of the ‘TAXUS Woman’ Analysis”. JACC: Coronary Interventions 2010; 312): 1250-1259.
Peer Reviewed Manuscripts
Mikhail GW, Gerber RT, Cox DA, Ellis SG, Lasala JM, Ormiston JA, Stone GW, Turco MA, Joshi AA, Baim DS, Colombo A. Influence of Gender on the Long-Term Outcomes after Percutaneous Coronary Intervention with the Paclitaxel Eluting Coronary Stent: Results of the “TAXUS Woman” Analysis. JACC Cardiovasc Interv 2010 Dec:3 (12): 1250-9.
Cyrus T, Mathews S, Lasala JM: Use of Mechanical Assist During High-Risk PCI and STEMI with Cardiogenic Shock. Catheterization and Cardiovascular Interventions 2010 Mar 1;75 Suppl 1 S1-6 Review.
Lasala JM, Cox DA, Morris DL, Breall JA, Mahoney PD, Horwitz PA, Shaw D, Hood KL, Mandinov L, Dawkins KD. Two-Year Results of Paclitaxel Eluting Stents in Patients with Medically Treated Diabetes Mellitus from the TAXUS ARRIVE Program. The American Journal of Cardiology: Volume 103, Issue 12, 15 June 2009 Pages 1663-1671.
Forman DE, Cox DA, Ellis SG, Lasala JM, Ormiston JA, Stone GW, Turco MA, Wei JY, Joshi AA, Dawkins KD, Baim DS. Long Term Paclitaxel-Eluting Stent Outcomes in Elderly Patients. Circulation: Cardiovascular Interventions, June 2009;2(3)178-187. Epub 2009 Jun 2.
Lasala JM, Cox D, Dobies D, Baran K, Bachinsky WB, Rogers E, Breall JA, Lewis DH, Song A, Starzyk RM and others. Stent thrombosis in routine practice: Outcomes and predictors through 2 years from the TAXUS ARRIVE registry program. Circulation online July 22, 2009 DOI:10.1161
Lasala JM, Cox D, Lewis, S.L., et al. Expanded Use of the TAXUS Express Stent: 2-year Insights on Safety from the 7500-Patient ARRIVE Registry Program. Eurointervention 2009 May;5 (1): 67-77.
Lasala JM, Cox DA, Dobies D, Baran K, Bachinsky WB, Rogers E, Breall JA, Lewis DH, Song A, Starzyk RM, Mascioli SR, Dawkins KD, Baim DS. Drug-Eluting Stent Thrombosis in Routine Clinical Practice: 2-Year Outcomes and Predictors from the TAXUS ARRIVE Registries. Circulation Cardiovasc Interv. 2009 Aug;2 (4):285-93 Epub 2009 Jul 22.
Percutaneous Closure of Complex Posttraumatic Muscular Ventricular Septal Defect. Muyskens S, Lasala JM, Balzer D. Catheterization and Cardiovascular Interventions 72:408-412 (2008)
Baran KW, Lasala JM, Cox DA, et al. A clinical risk score for prediction of stent thrombosis. Am J Cardiol 2008; 102:541-5
Lasala JM, Cox D, Morris D, Breall J, Mahoney P, Horwitz P, Shaw D, Hood K, Mandinov L, Dawkins K. Long-term benefit of Paclitaxel-eluting stents in patients with medically treated diabetes mellitus: Two year Results from the TAXUS ARRIVE Program. J Am Coll Cardiol 2009 June 15; 103(12):1663- 71 Epub 2009 April 16.
Lasala JM, Cox D, Dobies D, Mulestein J, Katopodis J, Revtyak G, Baim D. Usage Patterns And 2-Year Outcomes with the TAXUS Express Stent: Results of the ARRIVE 1 Registry. Catheterization and Cardiovascular Interventions 2008;72 (4): 433-445 (Oct 1 2008)
Hermiller J, Kar S, Fail P, Bajwa T, Smalling R, Lasala JM, Lim S, Kipperman R, Herrmann H, Whitlow P, Foster E, Glower D, Feldman T. Percutaneous Mitral Repair with the MitraClip Device for Functional Mitral Regurgitation: Acute Success and One-Year Durability in the Initial EVEREST Cohort. Submitted to JACC, February 15, 2008
Percutaneous Closure of Complex Posttraumatic Muscular Ventricular Septal Defect. Muyskens S, Lasala JM, Balzer D. Catheterization and Cardiovascular Interventions 72:408-412 (2008)
Baran KW, Lasala JM, Cox DA, et al. A clinical risk score for prediction of stent thrombosis. Am J Cardiol 2008; 102:541-5
Lasala JM, Stone GW, Dawkins KD, Serruys PW, Colombo A, Grube E, Koglin J, Ellis S. An Overview of the TAXUS Express, Paclitaxel-Eluting Stent Clinical Trial Program. Journal of Interventional Cardiology. 2006; 19(5): 422-431.
Zajarias A, Thanigaraj S, Lasala JM, Perez J: Predictors and Clinical Outcomes of Residual Shunt in Patients Undergoing Percutaneous Transcatheter Closure of Patent Foramen Ovale. Journal of Invasive Cardiology, Nov;18,(11), 533-7.
For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. John M. Lasala